JPRN-UMIN000053395Not yet recruitingUnknown
ENSURE-GA2 study - ENSURE-GA2 study
CS-Lung0 sites400 target enrollmentStarted: January 19, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 400
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 75years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1)Patients with dimentia (2)Patients with psychiatric disorder (3)Any other patients who are regarded as unsuitable for this study by the investigators
Investigators
Similar Trials
Completed
Not Applicable
The cluster randomized trial for elderly NSCLC patient using geriatric assessments.on-small cell lung cancerJPRN-UMIN000037590EJSG CS-Lung1,021
Not yet recruiting
Not Applicable
GA2LEN SURVEY FOLLOW UP STUDYrhinosinusitis1000170810046304AsthmaNL-OMON32137ondon imperial college: Respiratory Epidemiology & Public Health400
Active, not recruiting
Phase 1
Randomized study of NGR-hTNF given alone or in combination with doxorubicin in sarcoma patientsocally advanced or metastatic Soft-tissue sarcoma in patients untreated or previously treated with one or more prior systemicregimen.MedDRA version: 14.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018851-88-GBMOLMED69
Active, not recruiting
Phase 1
GR016: Randomized phase II study evaluating two doses of NGR-hTNF administered either as single agent or in combination with doxorubicin in patients with advanced soft-tissue sarcoma (STS). - NGR016MedDRA version: 9.1Level: HLGTClassification code 10041299ocally advanced or metastatic STS patients untreated or previously treated with one or more prior systemic regimen.EUCTR2010-018851-88-ITMOLMED96
Active, not recruiting
Phase 1
Estudio de fase 2, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, de 10 semanas, para evaluar el grado de alivio sintomático y la seguridad y tolerabilidad de SMP-986 (20 mg, 40 mg, 80 mg y 120 mg) administrado una vez al día durante 8 semanas en pacientes con síndrome de vejiga hiperactivaA 10-week randomised, double-blind, parallel-group, placebo-controlled phase 2 study to investigate the extent of symptom relief and the safety and tolerability of SMP-986 (20 mg, 40 mg, 80 mg and 120 mg) administered once daily for 8 weeks to patients with overactive bladder syndrome - Prueba de concepto de fase 2 de SMP-986 en pacientes con SVHASíndrome de vejiga hiperactiva (SVHA)Overactive Bladder SyndromeMedDRA version: 8.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2006-003730-15-ESDainippon Sumitomo Pharma Europe Ltd.710